Development of a truly effective anti-cocaine medication has been very challenging, particularly for treatment of cocaine overdose. There is still no FDA-approved anti-cocaine medication. Enhancing cocaine metabolism by administration of butyrylcholinesterase (BChE) has been recognized as a promising treatment strategy for cocaine abuse. However, the catalytic activity of this plasma enzyme is low against the naturally occurring (-) - cocaine. Our recent integrated computational-experimental effort has led to discovery of high-activity mutants of human BChE, known as cocaine hydrolases (CocHs), with >1,000-fold improved catalytic efficiency against cocaine compared to wild-type BChE. In vivo evidences indicate that our discovered CocHs are promising candidates for development of an anti-cocaine medication, especially for the overdose treatment. In this proposed project, we focus on the selection and optimization of the most promising CocH as a novel therapeutic candidate for cocaine overdose treatment through a combined use of various in silico, in vitro, and in vivo approaches.
The specific aims are: (1) To prepare and characterize the discovered CocHs in vitro for their catalytic activity and stability;(2) To characterize the CocHs in vivo for their potency, biological/circulatory half-lives, and immunogenicity by using the CocH materials prepared in Aim 1;(3) To design, prepare, and characterize new CocH entities that have not only a high in vivo potency, but also a higher thermal stability and a longer circulatory half-life without immunogenicity. Accomplishment of this proposed investigation will result in the identification and development of the most promising CocH entity that has a high in vivo potency in the protective and rescuing effects, a high stability, and a sufficiently long biological half-life without immunogenicity. The CocH entity optimized in this investigation is expected to be highly effective and safe as an exogenous enzyme for cocaine overdose treatment in humans.
Accelerating cocaine metabolism has been recognized as a promising treatment strategy for anti-cocaine medication. Accomplishment of the proposed investigation will result in the identification of reliable candidates of a novel enzyme therapy for cocaine overdose.
|Zheng, Fang; Zhan, Chang-Guo (2016) Reply to Curry and Coombs: Benzoic acid is formed predominantly from the benzoyl ester hydrolysis in the presence of cocaine hydrolase. Proc Natl Acad Sci U S A 113:E2102-3|
|Yuan, Yaxia; Quizon, Pamela M; Sun, Wei-Lun et al. (2016) Role of Histidine 547 of Human Dopamine Transporter in Molecular Interaction with HIV-1 Tat and Dopamine Uptake. Sci Rep 6:27314|
|Zheng, Xirong; Deng, Jing; Zhang, Ting et al. (2016) Potential anti-obesity effects of a long-acting cocaine hydrolase. Chem Biol Interact 259:99-103|
|Chen, Xiabin; Zheng, Xirong; Zhou, Ziyuan et al. (2016) Effects of a cocaine hydrolase engineered from human butyrylcholinesterase on metabolic profile of cocaine in rats. Chem Biol Interact 259:104-109|
|Zhang, Yuxin; Huang, Xiaoqin; Han, Keli et al. (2016) Free energy profiles of cocaine esterase-cocaine binding process by molecular dynamics and potential of mean force simulations. Chem Biol Interact 259:142-147|
|Wang, Guojun; Zhang, Ting; Huang, Haifeng et al. (2016) Plant expression of cocaine hydrolase-Fc fusion protein for treatment of cocaine abuse. BMC Biotechnol 16:72|
|Yao, Jianzhuang; Yuan, Yaxia; Zheng, Fang et al. (2016) Unexpected Reaction Pathway for butyrylcholinesterase-catalyzed inactivation of ""hunger hormone"" ghrelin. Sci Rep 6:22322|
|Chen, Xiabin; Xue, Liu; Hou, Shurong et al. (2016) Long-acting cocaine hydrolase for addiction therapy. Proc Natl Acad Sci U S A 113:422-7|
|Wei, Donghui; Tang, Mingsheng; Zhan, Chang-Guo (2015) Fundamental reaction pathway and free energy profile of proteasome inhibition by syringolin A (SylA). Org Biomol Chem 13:6857-65|
|Chen, Xiabin; Huang, Xiaoqin; Geng, Liyi et al. (2015) Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase. Biochem J 466:243-51|
Showing the most recent 10 out of 42 publications